Skip to main content
Equibles
NTRA logo

NTRA · Natera, Inc. · Investor Relations

Track NTRA — free

Use NTRA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NTRA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$319.09 -3.85 (-1.19%) At close · Nov 13 Play latest call Q3 2026 earnings call transcript
Russell 1000 member Rebalance outlook locked
Market Cap
$46.27B
Shares
145.00M
Volume · Nov 13 1.69M Avg daily vol (3M) 1.72M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-10 Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
2026-11-05 Natera Announces Leadership Transition
2026-11-05 Natera Reports Third Quarter 2026 Financial Results
2026-11-05 Signatera™ Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers
2026-11-04 Signatera™ in Head and Neck Cancer: Three New Publications Demonstrate Strong Clinical Performance and Actionability
2026-11-03 Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
2026-10-29 Natera to Report its Third Quarter Results on November 5, 2026
2026-10-27 Signatera™ Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer
2026-10-26 Natera Shares Real-World Analyses and Data at ASN Kidney Week 2026, Highlighting the Critical Need for Genetic Testing with Renasight™
2026-10-18 ESMO 2026 Presentations Deepen the Evidence Base for Natera’s Oncology Portfolio and Leadership in Ultrasensitive MRD Technology
2026-10-15 Natera’s Signatera™ MRD Test Named to TIME’s List of the Best Inventions of 2026
2026-10-13 Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer
2026-10-09 FDA Grants Breakthrough Device Designation for Natera’s Multi-Cancer Early Detection Assay
2026-10-07 Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma
2026-10-06 New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists
2026-10-05 Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
2026-09-22 Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
2026-09-18 Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for Signatera™
2026-09-01 New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
2026-08-28 Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
2026-08-27 Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
2026-08-12 Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
2026-08-06 Natera Reports Second Quarter 2026 Financial Results
2026-08-05 Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
2026-07-30 Natera to Report its Second Quarter Results on August 6, 2026

Past events

Date Event Type
2026-11-10 8th Annual Wolfe Research Healthcare Conference Conference
2026-11-09 UBS Global Healthcare Conference Conference
2026-11-05 Natera, Inc. Q3 Earnings Conference Call Earnings call
2026-09-15 Baird 2026 Global Healthcare Conference Conference
2026-09-14 Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-08-12 Canaccord Genuity 46th Annual Growth Conference Conference
2026-08-06 Natera, Inc. Q2 Earnings Conference Call Earnings call
2026-06-08 Goldman Sachs 47th Annual Global Healthcare Conference Conference
2026-05-07 Natera, Inc. Q1 Earnings Conference Call Earnings call
2026-03-10 Leerink Partners Global Healthcare Conference 2026 Conference
2026-03-04 Raymond James 47th Annual Institutional Investors Conference Conference
2026-03-03 TD Cowen 46th Annual Health Care Conference Conference
2026-02-26 Natera, Inc. Q4 Earnings Conference Call Earnings call
2026-01-14 44th Annual J.P. Morgan Healthcare Conference Conference
2025-12-03 37th Annual Piper Sandler Healthcare Conference Conference
2025-11-19 Wolfe Research Healthcare Conference Conference
2025-11-18 Jefferies Global Healthcare Conference in London Conference
2025-11-11 UBS Global Healthcare Conference Conference
2025-11-06 Natera, Inc. Q3 Earnings Conference Call Earnings call
2025-10-23 Natera Post-ESMO Investor Call Event
2025-09-23 Bernstein 2nd Annual Healthcare Forum Event
2025-09-09 Baird 2025 Global Healthcare Conference Conference
2025-09-08 Morgan Stanley 23rd Annual Global Healthcare Conference Conference
2025-08-12 Canaccord Genuity 45th Annual Growth Conference Conference
2025-08-07 Natera, Inc. Q2 Earnings Conference Call Earnings call

Source: https://investor.natera.com/overview/default.aspx

Key facts CIK 1604821 CUSIP 632307104 13F (30d) 729 filings 674 filers Visit website Investor relations